光介导治疗，如光动力疗法（PDT），被视为新兴的癌症治疗策略。然而，常见的光敏剂（PSs）仍存在许多缺陷，如发射波长短、光稳定性弱、细胞渗透性差和PDT效率低。因此，开发高性能的光敏剂非常重要。最近，具有聚集诱导发光（AIE）特性和红/近红外（NIR）发射的发光剂被报道为有前景的图像引导的癌症治疗光敏剂，因为它们能够防止在生理环境中发生自体荧光，聚集状态下的增强荧光以及产生活性氧物种（ROS）。在此，我们开发了名为TBTCPM和MTBTCPM的光敏剂，它们具有供体-受体（D-A）结构，强烈的红光/近红外光谱，优异的特异性靶向性能，良好的细胞渗透性和高光稳定性。有趣的是，在白光照射下，这两种光敏剂均能够高效产生活性氧物种，并对癌细胞具有出色的杀伤效果。因此，此研究不仅展示了在细胞图像引导的PDT癌症治疗中的应用性能，还为构建具有长发射波长的聚集诱导发光物质提供了策略。本文受版权保护，保留所有权利。

Light-mediated therapies such as photodynamic therapy (PDT) is considered as emerging cancer treatment strategies. However, there are still lots of defect with common photosensitizers (PSs), such as short emission wavelength, week photostability, poor cell permeability and low PDT efficiency. Therefore, it is very important to develop high-performance PSs. Recently, luminogens with aggregation-induced emission (AIE) characteristics and Red/near-infrared (NIR) emissive have been reported as promising PSs for image-guided cancer therapy, due to prevent autofluorescence in physiological environments, their enhanced fluorescence in the aggregated state and generation of reactive oxygen species (ROS). Herein, we developed PSs named TBTCPM and MTBTCPM with donor-acceptor (D-A) structures, strong Red/near intra-red (NIR), excellent targeting specificities to good cell permeability and high photostability. Interestingly, both of them can efficiently generate reactive oxygen species under white light irradiation and possess excellent killing effect on cancer cells. This study, thus, not only demonstrates applications in cell image-guided PDT cancer therapy performances. but also provide strategy for construction of AIEgens with long emission wavelengths.This article is protected by copyright. All rights reserved.